- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03023189
Efficacity and Safety of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding (EXARHOSE)
Efficacy and Safety of Early Administration of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding: a Multicenter, Randomized, Double Blind, Placebo-controlled Trial (Modified by amendment1)
Upper digestive bleeding. Upper gastrointestinal haemorrhage is a common cause of decompensated cirrhosis and is associated with a high mortality rate among cirrhotic patients. Its leading cause is the rupture of gastro-esophageal varices due to portal hypertension. In cirrhotic patients, the management of acute gastrointestinal haemorrhage is challenging as they often present with coagulation (or haemostasis abnormalities) abnormalities such as hyperfibrinolysis, especially when the cirrhosis is decompensated. Beyond life support measures, therapeutic modalities of upper gastrointestinal bleeding rely on both endoscopic and pharmacological interventions. Tranexamic acid (TA) is an antifibrinolytic that may help control the bleeding in this setting, as it showed an unquestionable benefit in other indications. TA has previously been studied in both upper gastrointestinal haemorrhage from any causes and in liver transplantation of cirrhotic patients. However, there is a lack of data to conclude on its effectiveness (or efficiency) in the early treatment of acute bleeding in cirrhotic patients.
Investigators hypothesize that, when given early, TA would be beneficial for cirrhotic patients presenting with acute upper gastrointestinal haemorrhage , by controlling the haemorrhage, avoiding rebleeding episodes and reducing mortality within 5 days after its administration. Moreover, TA could prevent early cirrhosis complications (such as hepatic encephalopathy, sepsis and ascites liquid infection, hepatorenal syndrome), could reduce indications to transjugular portosystemic shunt (TIPS), shorten the length of stay in intensive care unit and the length of hospitalization, and decrease late relapses and one-year mortality.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Acute Upper gastrointestinal haemorrhage (UGIH) is frequent, with an estimated annual incidence of 150/100 000 in France. Its second etiology is the rupture of portal hypertension-related gastro-esophageal varices, accounting for 20 % of the patients and responsible for more than 50 % of the hospitalizations in intensive care unit (ICU) for UGIH.
In cirrhotic patients, variceal bleeding is the main cause of UGIH (over 70 %) and death (30 %), which occurs in the most severe patients (Child-Pugh score B or C and/or high MELD score, and high levels of portal hypertension).
Acute UGIH is directly responsible for 50 % of the deaths, either because it remains uncontrolled during the acute phase (within 5 days), or because of early relapses (within 6 weeks). Every episode of acute UGIH worsens the middle and long-term vital prognosis: about 60 % of the patients present with UGIH recurrence within one year and the survival rate is only 30 % 3 years after the first episode.
Moreover, acute UGIH is a triggering factor for several severe cirrhosis-specific complications (such as hepatic encephalopathy, sepsis and ascites liquid infection, hepatorenal syndrome), which themselves lead to high mortality rates. Despite the improvement of preventive, diagnostic and therapeutic strategies, UGIH remains stable in France.
The haemostasis of cirrhotic patients is often abnormal at baseline : thrombopenia, decrease of factors II, V, VII, IX, X and XI, decrease of fibrinolytic proteins, increase of factor VIII and spontaneous fibrinolysis. When compensated, the cirrhotic's haemostasis remains globally preserved, due to the balance of pro and anticoagulant alterations.
Every cause of cirrhosis decompensation, such as acute PHT-UGIH, can increase hemostatic disorders, leading to hyperfibrinolysis. This could slow down or inhibit the clotting, thus disrupting pharmacological control of acute UGIH.
TA could be efficient in acute UGIH of cirrhotic patients. It is a simple antifibrinolytic which showed clinical benefits on haemorrhage and/or mortality in several other indications (surgical, obstetrical and traumatic). It is now widely used according to recommendations.
Early administration of TA seems to be beneficial in UGIH haemorrhage. Despite theoretical efficiency, 4 recent Cochrane meta-analysis concluded to the lack of significant data (poor overall trials quality). The benefit of the use of TA in acute UGIH (and acute PHT-UGIH) remains uncertain.
At this day, TA has still not been studied in acute UGIH of cirrhotic patients, although it showed benefits on blood transfusion's requirements and on haemorrhagic complications during liver transplantation (for which cirrhosis most frequent cause).
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Matthieu HEIDET, MD
- Email: matthieu.heidet@aphp.fr
Study Contact Backup
- Name: Roland Amathieu, MD
- Email: roland.amathieu@aphp.fr
Study Locations
-
-
-
Bondy, France, 93140
- Recruiting
- Jean Verdier Hospital
-
Contact:
- Roland Amathieu, MD
- Email: roland.amathieu@aphp.fr
-
Creteil, France, 94010
- Recruiting
- Henri Mondor Hospital
-
Contact:
- Matthieu HEIDET, MD
- Email: matthieu.heidet@aphp.fr
-
Melun, France, 77000
- Recruiting
- Marc Jacquet Hospital
-
Contact:
- Line JACOB, MD
- Email: line.jacob@ch-melun.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria (modified by amendment1)
- Age ≥ 18
- Patient treated by a prehospital physician-staffed SMUR team, a firefighter physician-staffed ambulance (ARBSPP), an hospital EMS or an ICU
- Acute upper digestive bleeding (< 24h) in the shape of hematemesis, described either by the physician, the patient, a relative or a member of the medical team
- Known or suspected cirrhosis (based on clinical/biological/radiographic/anamnestic data)
- Affiliated or recipient of the French social security
- Written consent (or under emergency procedures)
Exclusion Criteria (modified by amendment1)
- Known ongoing pregnancy or breastfeeding
- TA already given (if inter-hospital transfer)
- Endoscopy already performed for the current haemorrhagic episode
- Hospitalization for over 24h in an intensive care unit or a routine care unit
- Exclusive lower digestive bleeding or melena only
- Patient in cardiac arrest at the arrival of the prehospital medical team, whether recovered or not
- Patient already randomised once in EXARHOSE study
TA Counter-indications
- creatininemia > 500 μmol/L or documented clearance < 30 mL/min
- documented ongoing CIVD (prior to UDB)
- ongoing seizures
- ongoing arterial or venous thrombosis
- allergy
- Known participation of the patient to another therapeutic study
- Known linguistic inability of the patient to understand the study
- Patient under known guardianship
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Tranexamic acid
At randomisation : loading dose of 1g of intravenous tranexamic acid for 10 min, immediately followed by an intravenous infusion of 3g of TA over 24h
|
At randomisation : loading dose of 1g of intravenous tranexamic acid for 10 min, immediately followed by an intravenous infusion of 3g of TA over 24h. Total dose : 4 g of TA |
Placebo Comparator: Placebo
At randomisation : loading dose of 10 mL of intravenous isotonic saline for 10 min, immediately followed by an intravenous infusion of 30 mL of isotonic saline over 24h
|
At randomisation : loading dose of 10 mL of intravenous isotonic saline for 10 min, immediately followed by an intravenous infusion of 30 mL of isotonic saline over 24h Total dose : 40 mL of Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The main outcome is a composite criterion and includes: control on acute bleeding, absence of re-bleeding episodes at day 5 and absence of death at day 5 (modified by amendment 1)
Time Frame: 5 days after randomisation
|
Specifically, the composite criterion is defined by all the following criteria:
|
5 days after randomisation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Control of the bleeding
Time Frame: Within 5 days after randomisation
|
At least 1 criterion present :
|
Within 5 days after randomisation
|
Re-bleeding episodes
Time Frame: At day 6, day 28, day 42, 3 months, 6 months and 1 year after randomisation
|
At day 6, day 28, day 42, 3 months, 6 months and 1 year after randomisation
|
|
Death
Time Frame: At day 6, day 28, day 42, 3 months, 6 months and 1 year after randomisation
|
At day 6, day 28, day 42, 3 months, 6 months and 1 year after randomisation
|
|
Fluid infusion volume (in mL)
Time Frame: At day 6, day 28 and day 42 after randomisation
|
At day 6, day 28 and day 42 after randomisation
|
|
Blood transfusion volume (in mL)
Time Frame: At day 6, day 28 and day 42 after randomisation
|
At day 6, day 28 and day 42 after randomisation
|
|
Blood transfusion quantity (number of units)
Time Frame: At day 6, day 28 and day 42 after randomisation
|
At day 6, day 28 and day 42 after randomisation
|
|
Nature of blood transfusion: - Red cells units - Platelets units - Fresh frozen plasma - Fibrinogen - Other
Time Frame: At day 6, day 28 and day 42, after randomisation
|
At day 6, day 28 and day 42, after randomisation
|
|
TIPS procedure (in Child-Pugh B patients)
Time Frame: At day 6, day 28, day 42 after randomisation
|
At day 6, day 28, day 42 after randomisation
|
|
Visceral and systemic complications
Time Frame: At day 6, day 28 and day 42, after randomisation (or until discharge)
|
Complications, defined as:
|
At day 6, day 28 and day 42, after randomisation (or until discharge)
|
Need for organ substitution - Renal replacement therapy (dialysis) - Liver replacement therapy - Mechanical ventilation
Time Frame: At day 6, day 28 and day 42, after randomisation (or until discharge)
|
At day 6, day 28 and day 42, after randomisation (or until discharge)
|
|
Liver transplantation
Time Frame: At day 6, day 28, day 42, 3 months, 6 months and 1 year after randomisation
|
At day 6, day 28, day 42, 3 months, 6 months and 1 year after randomisation
|
|
Length of stay in ICU (in days)
Time Frame: At day 6, day 28, day 42, 3 months, 6 months and 1 year after randomisation
|
At day 6, day 28, day 42, 3 months, 6 months and 1 year after randomisation
|
|
Duration of hospitalization (in days)
Time Frame: At day 6, day 28, day 42, 3 months, 6 months and 1 year after randomisation
|
At day 6, day 28, day 42, 3 months, 6 months and 1 year after randomisation
|
|
Number of participants with treatment-related adverse events as assessed by the ANSM notice of Exacyl®
Time Frame: up to 5 days
|
Adverse events as assessed by the ANSM notice of Exacyl® are :
Adverse effects will be systematically searched for and collected in the electronic Case Report Form (eCRF) during the acute phase (within 5 days after randomization), as assessed by the AP-HP notification form. When present, investigators will have to send a notification to the promoter (by fax). Patients with severe adverse effects (leading to death, life-threatening condition, hospitalization and pursuit of hospitalization, incapacity or handicap, congenital malformation) will be followed until disappearance of these. Every document related to the patient during the protocol should be transmitted to the promoter. Investigators are supposed to answer every inquiry of the promoter. |
up to 5 days
|
Delay between the beginning of the haemorrhage and the initiation of the AT treatment
Time Frame: At day 1
|
At day 1
|
Collaborators and Investigators
Investigators
- Principal Investigator: Matthieu HEIDET, Assistance Publique - Hôpitaux de Paris
Publications and helpful links
General Publications
- Heidet M, Amathieu R, Audureau E, Augusto O, Nicolazo de Barmon V, Rialland A, Schmitz D, Pierrang F, Marty J, Chollet-Xemard C, Thirion O, Jacob L. Efficacy and tolerance of early administration of tranexamic acid in patients with cirrhosis presenting with acute upper gastrointestinal bleeding: a study protocol for a multicentre, randomised, double-blind, placebo-controlled trial (the EXARHOSE study). BMJ Open. 2018 Aug 10;8(8):e021943. doi: 10.1136/bmjopen-2018-021943.
- Heidet M, Mermet E, Vaux J, Jeremie R, Audureau E, Marty J. Simulated EMS response times until patients located in public train stations: A geospatial model to improve on-foot accessibility. Resuscitation. 2018 Oct;131:e3-e5. doi: 10.1016/j.resuscitation.2018.07.031. Epub 2018 Aug 2. No abstract available.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P150959
- 2016-002677-35 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cirrhosis
-
Postgraduate Institute of Medical Education and...Society for the Study of Liver Diseases, Chandigarh ( India )UnknownDecompensated Cirrhosis of LiverIndia
-
University Health Network, TorontoUnknown
-
National Institute of Diabetes and Digestive and...National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Cancer... and other collaboratorsRecruitingCirrhosis | Cirrhosis, Liver | Cirrhosis Due to Hepatitis B | Cirrhosis Due to Hepatitis C | Cirrhosis Early | Cirrhosis Advanced | Cirrhosis Infectious | Cirrhosis Alcoholic | Cirrhosis, Biliary | Cirrhosis Cryptogenic | Cirrhosis Due to Primary Sclerosing CholangitisUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingPrimary Biliary CirrhosisChina
-
Northwestern UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); National Cancer... and other collaboratorsRecruitingCirrhosis | Cirrhosis, Liver | Cirrhosis Due to Hepatitis B | Cirrhosis Due to Hepatitis C | Cirrhosis Early | Cirrhosis Advanced | Cirrhosis Infectious | Cirrhosis Alcoholic | Cirrhosis, Biliary | Cirrhosis Cryptogenic | Cirrhosis Due to Primary Sclerosing CholangitisUnited States
-
RenJi HospitalNot yet recruiting
-
Nanfang Hospital, Southern Medical UniversityRecruiting
-
Institute of Liver and Biliary Sciences, IndiaRecruiting
-
SUUMC Central Military Hospital Dr Carol DavilaRecruiting
-
The Cleveland ClinicRecruiting
Clinical Trials on Tranexamic acid
-
Icahn School of Medicine at Mount SinaiRecruiting
-
University of LiegeCompletedArthroplasty Complications | Hemorrhage Postoperative | Total Blood LossBelgium
-
London School of Hygiene and Tropical MedicineCompleted
-
Samsung Medical CenterUnknownBleeding | Transfusion Related ComplicationKorea, Republic of
-
Assiut UniversityCompleted
-
Thammasat UniversityCompleted
-
Ferring PharmaceuticalsCompleted
-
Ain Shams UniversityCompleted
-
Aswan University HospitalCompletedCesarean Section ComplicationsEgypt
-
London School of Hygiene and Tropical MedicineRawalpindi Medical CollegeCompletedPregnancy, High RiskPakistan, Zambia